Two types of alterations of SYK expression are consistently associated with breast malignancy: (a) In a subset of breast cancers, SYK expression is lost due to aberrant SYK gene promoter hypermethylation that leads to silencing of SYK expression. The loss of expression is associated with increased invasiveness of breast cancer cells. (B) Altered SYK expression is also reflected by the addition of short form Syk [Syk(S)] in breast tumors in contrast to only the long form Syk [Syk(L)] expression in normal mammary tissues. Syk(S) is generated by alternative splicing that results in an in-frame deletion of 23 residues within the interdomain B (IDB) of Syk. Expression of Syk(L) but not Syk(S) inhibits tumor cell invasion and tumorigenicity. The tyrosine kinase activity of Syk is responsible for the invasion suppression function of Syk(L). Consistent with their differential effects on invasion, Syk(L) but not Syk(S) is able to induce tyrosine phosphorylation in breast cancer cells. These studies lead us to postulate that the downstream phosphorylation targets for Syk(L) mediate Syk(L) anti-invasion functions. Also, the inability of Syk(S) to phosphorylate in vivo targets despite an intact kinase domain suggests a critical role of IDB in mediating the process of phosphorylation by Syk(L). In this proposal, we will define the biological roles of Syk in control of tumor-associated phenotypes. A potential oncogenic activity of Syk(S) will also be assessed (Aim 1.1). We will further analyze the interplay of the two Syk isoforms (Aim 1.2). We will also establish an association of Syk isoform expression and the pathological features of breast tumors (Aim 1.3). Phosphorylation targets for Syk that are responsible for Syk(L)-inducible tumor (invasion) suppression will be searched for. We will purify these proteins by immuno-affinity method coupled with mass spectrometry sequencing (Aim 2.1). The participation of these targets in SYK signaling and Syk(L) phenotypic responses will then be analyzed (Aim 2.2). To elucidate the mechanism of differential in vivo phosphorylation and biological responses by Syk(L) and Syk(S), we will analyze the role IDB in SYK signaling in breast cancers. We will search for proteins that interact with the IDB of Syk(L) in mammary epithelial cells (Aim 3.1). How these IDBinteracting proteins assist in Syk(L)-mediated phosphorylation and the resultant phenotypes will be analyzed (Aim 3.2). Taken together, these studies should clarify the mechanisms by which the loss of Syk(L) and aberrant expression of Syk(S) promotes breast cancer progression. ? ?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA100278-01
Application #
6597788
Study Section
Pathology B Study Section (PTHB)
Program Officer
Ault, Grace S
Project Start
2003-06-01
Project End
2008-05-31
Budget Start
2003-06-01
Budget End
2004-05-31
Support Year
1
Fiscal Year
2003
Total Cost
$266,057
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Pathology
Type
Other Domestic Higher Education
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Pan, Yong; Weinman, Edward J; Dai, Jia Le (2008) Na+/H+ exchanger regulatory factor 1 inhibits platelet-derived growth factor signaling in breast cancer cells. Breast Cancer Res 10:R5
Yuan, Yunfei; Wang, Jianping; Li, Jinqing et al. (2006) Frequent epigenetic inactivation of spleen tyrosine kinase gene in human hepatocellular carcinoma. Clin Cancer Res 12:6687-95
Pan, Yong; Wang, Lei; Dai, Jia Le (2006) Suppression of breast cancer cell growth by Na+/H+ exchanger regulatory factor 1 (NHERF1). Breast Cancer Res 8:R63
Yuan, Yunfei; Liu, Hongji; Sahin, Aysegul et al. (2005) Reactivation of SYK expression by inhibition of DNA methylation suppresses breast cancer cell invasiveness. Int J Cancer 113:654-9
Wang, Lei; Devarajan, Eswaran; He, Jin et al. (2005) Transcription repressor activity of spleen tyrosine kinase mediates breast tumor suppression. Cancer Res 65:10289-97
Dai, Jia Le; Wang, Lei; Sahin, Aysegul A et al. (2004) NHERF (Na+/H+ exchanger regulatory factor) gene mutations in human breast cancer. Oncogene 23:8681-7